Core Viewpoint - Brazil is set to launch a single-dose dengue vaccine by the end of January 2026, with an initial investment of 368 million reais and plans to provide 3.9 million doses through the public healthcare system [1][2]. Group 1: Vaccine Development and Efficacy - The Butantan-DV vaccine, developed by the Butantan Institute, is the only approved single-dose dengue vaccine globally, effective against all four types of dengue [1]. - Clinical studies indicate an overall efficacy of 74.7% against dengue cases, 91.6% against severe cases, and 100% efficacy for hospitalizations due to dengue [1]. Group 2: Vaccination Rollout and Collaboration - Initial vaccination efforts will focus on healthcare workers in specific cities, including Botucatu and Maranguape, with plans to expand to the general population as production capacity increases [2]. - The production of the vaccine is a collaboration between the Butantan Institute and China's WuXi Biologics, aiming to supply approximately 30 million doses by the second half of 2026 [2]. Group 3: Public Health Context - There was a significant increase in dengue cases in Brazil last year, with a reported 1,660,190 suspected cases as of December 26, 2025, despite a 75% decrease compared to the previous year [2]. - The Brazilian Ministry of Health emphasizes that vaccination will be part of a broader strategy that includes vector control, environmental management, and public health education [2].
巴西将启动单剂次登革热疫苗接种 中企助力疫苗产能提升
Zhong Guo Xin Wen Wang·2025-12-27 08:06